Despite increasing cure rates for many paediatric solid tumours, metastatic disease and certain histologies carry a poor prognosis and require new therapies. The use of new cytotoxic agents in children is based on preclinical data and evaluations in adults ([Smith *et al*, 1998](#bib36){ref-type="other"}).

Temozolomide (Temodal®, Temodar®) is an orally administered imidazotetrazinone second-generation alkylating agent that is spontaneously converted to 5-(3-metyltriazen-1-yl)imidazole-4-carboxamide (MTIC) at physiological pH, and therefore does not require hepatic metabolism for activation. Its ability to cross the blood--brain barrier is of special interest with respect to its activity in central nervous system tumours ([Patel *et al*, 2003](#bib30){ref-type="other"}). Temozolomide has shown activity in preclinical models and in clinical trials in patients with malignant gliomas and melanoma ([Newlands *et al*, 1992](#bib22){ref-type="other"}; [O\'Reilly *et al*, 1993](#bib29){ref-type="other"}; [Bleehen *et al*, 1995](#bib1){ref-type="other"}). Phase I and II clinical trials in children and adolescents demonstrated tumour responses in malignant gliomas ([Estlin *et al*, 1998](#bib9){ref-type="other"}; [Nicholson *et al*, 1998](#bib23){ref-type="other"}; [Lashford *et al*, 2002](#bib16){ref-type="other"}).

The cytotoxicity and antitumour activity of temozolomide is determined largely by methylation of DNA at the *O*^6^-position of guanine and the mismatch repair system, and is inversely related to the activity of the DNA repair protein *O*^6^-Alkyguanine-DNA alkyltransferase (also known as *O*^6^-methylguanine-DNA methyltransferase (MGMT)) ([Karran and Hampson, 1996](#bib14){ref-type="other"}; [Pegg, 2000](#bib31){ref-type="other"}; [Gerson, 2002](#bib12){ref-type="other"}; [Tentori and Graziani, 2002](#bib37){ref-type="other"}). Modulation of MGMT activity using pseudosubstrate inhibitors such as *O*^6^-benzylguanine (O^6^BG) ([Dolan *et al*, 1994](#bib7){ref-type="other"}) and more recently *O*^6^-(4-bromothenyl)guanine (PaTrin-2) ([Middleton *et al*, 2000a](#bib20){ref-type="other"}) results in depletion of MGMT and increased sensitivity to DNA alkylating or crosslinking agents, including temozolomide, carmustine, lomustine ([Dolan *et al*, 1990](#bib8){ref-type="other"}; [Plowman *et al*, 1994](#bib33){ref-type="other"}; [Liu *et al*, 1996](#bib18){ref-type="other"}; [Wedge *et al*, 1996](#bib43){ref-type="other"}) and cisplatin ([D\'Atri *et al*, 1995](#bib6){ref-type="other"}; [Fishel *et al*, 2003](#bib10){ref-type="other"}). The latter is supported by the observation that MGMT expressing cells are more resistant to the toxic effects of cisplatin ([Preuss *et al*, 1996](#bib34){ref-type="other"}). Cisplatin itself has been reported to inactivate MGMT in HeLa cells ([Wang and Setlow, 1989](#bib41){ref-type="other"}) and to increase the sensitivity of human leukemic blasts to triazene compounds ([Piccioni *et al*, 1995](#bib32){ref-type="other"}). In Jurkat cells, decreased MGMT activity was associated with the attenuation of expression of MGMT mRNA ([D\'Atri *et al*, 2000](#bib5){ref-type="other"}). These observations have suggested the possibility of a synergistic antitumour activity of cisplatin with temozolomide and have led to a phase I clinical trial of this combination in adult patients with advanced solid malignancies ([Britten *et al*, 1999](#bib4){ref-type="other"}). The combination was not associated with enhanced toxicity and showed activity in patients with carcinomas and sarcoma.

The present report presents the clinical results of a phase I/II trial of the cisplatin--temozolomide combination in paediatric patients with refractory or recurrent solid tumours. The objectives were to define toxicity profiles and maximum tolerated doses (MTDs), and to recommend a safe dose for phase II testing. In order to perform a single study for two patient cohorts, heavily and nonheavily pretreated patients, we chose a two stage, two group continual reassessment method (CRM) design ([O\'Quigley *et al*, 1999](#bib28){ref-type="other"}; [O\'Quigley and Paoletti, 2003](#bib26){ref-type="other"}). This model-based adaptive experimental design is used in cancer trials as an alternative to more conventional approaches because it provides a combination of efficiency, safety and the use of information obtained from all treated subjects. To date, there is little experience on the use of the CRM in paediatric oncology trials. We also undertook pharmacodynamic measurements of MGMT activity in peripheral blood mononuclear cell (PBMC), because of its possible role in toxicity and response to both cisplatin and temozolomide, and to further examine the effect of cisplatin on MGMT expression.

PATIENTS AND METHODS
====================

Patient eligibility
-------------------

Eligible patients were required to have a cytologically and/or histologically confirmed diagnosis of a malignant solid tumour (except brain stem tumours with clinical and radiological diagnosis), which was refractory or in relapse after standard treatment, and/or for which no effective treatment was available. Two cohorts were distinguished: less heavily treated (cohort A) and heavily treated (cohort B) patients, the latter defined by prior craniospinal irradiation (CSI) and/or high-dose chemotherapy with stem cell rescue. Early in the study, the definition of cohort B was modified by including patients with disease invasion to the marrow. Following increased haematological toxicity, it was reasonable to assign them to cohort B rather than to the initial cohort A. Patients were to be between 6 months and 21 years of age with ECOG or Lansky performance status of ⩽2 or ⩾50%, respectively, and a life expectancy \>6 weeks. Patients were required to have adequate haematopoietic function, that is, neutrophils \>1.0 × 10^9^ l^−1^ and platelets \>100 × 10^9^ l^−1^, satisfactory hepatic function, that is, bilirubin ⩽1.5 upper normal limit (UNL), transaminases ⩽2.5 × UNL, normal renal function including normal creatinine clearance (\>70 ml min^−1^/1.73 m^2^), audiogram ⩽grade 2, and no radiotherapy or chemotherapy within the last 4 weeks before study entry (6 weeks for nitrosoureas). Noninclusion criteria included severe infection, symptomatic or evolutive intracranial hypertension, prior treatment with cisplatin ⩾400 mg m^−2^.

Before study enrollment, complete medical history and clinical examination, concomitant treatments, performance status, haematologic and biochemical profile, clotting rates, creatinine clearance, audiogram, ECG, chest-X-ray, and tumour target assessment were ascertained. The study was conducted in six centers in France in accordance with the Good Clinical Practices and approved by the local Ethics Committee. Patient or parents or the legal representative provided a written informed consent, and patient assent was obtained, when appropriate.

Treatment
---------

Cisplatin was purchased in vials of 100 mg ml^−1^. The calculated dose was diluted in 180 ml m^−2^ of normal saline. On day 0 of treatment, 480 ml m^−2^ glucose 5% and electrolyte infusion solution was administered prior to the cisplatin solution, which was given over 180 min simultaneously with 180 ml m^−2^ 10% mannitol. This was followed by 180 ml m^−2^ of normal saline and 10% mannitol. Temozolomide (Temodal®) was supplied by Schering-Plough Laboratory (Levallois, France) as white-opaque, hard gelatin capsules in strengths of 5, 20, and 100 mg. The calculated doses were rounded to the nearest 5 mg. For children having difficulties in swallowing, it was allowed to open the capsules and administer the drug in apple juice or stewed fruit. Temozolomide was administered p.o. on days 1--5 to patients who fasted for at least 4 h before and 30 min after each dose. Treatment was repeated every 28 days.

Concomitant antiemetic treatments included ondansetron and prednisone i.v. before cisplatin, and ondansetron p.o. on days 1--5 before temozolomide.

In the event of dose-limiting toxicity (DLT) (defined below), the next cycle was delayed and the doses of cisplatin and temozolomide reduced to the next lowest dose level. If neutrophils or platelets at day 28 were \<1.0 × 10^9^ or \<100 × 10^9^ l^−1^, respectively, the next cycle was delayed until recovery. In the case of hearing loss or reduction of renal function (grade 3) or at a cumulative cisplatin dose of 600 mg m^−2^, cisplatin treatment was discontinued and treatment pursued with temozolomide alone.

Experimental study design
-------------------------

The overall objective was to determine for each cohort (A and B) the recommended dose level for phase II testing by using a two stage, two group CRM ([O\'Quigley *et al*, 1999](#bib28){ref-type="other"}; [O\'Quigley and Paoletti, 2003](#bib26){ref-type="other"}). The MTD was defined as the dose level closest to that producing a DLT in one patient in five on average. The starting dose was 80 mg m^−2^ cisplatin and 150 mg m^−2^ day^−1^ temozolomide for 5 consecutive days (level 1), corresponding to 80% of the recommended dose in single treatments, with planned dose escalation to 80/200 (level 2) and 100/200 (level 3), respectively. Patients of both cohorts were initially treated as a single group for dose escalation. After DLT occurred, the design was switched to escalation/de-escalation according to the two sample CRM model. After each new toxicity evaluation, the best estimates of the MTD in the two groups were reassessed. Information obtained at all levels was used in determining the most appropriate level at which to treat the next patient or group of patients. Early determination rules allowed the study to close when, for either of the cohorts, inclusion would not result in allocation to any level other than the one currently in use with a probability close to 0.9 ([O\'Quigley and Reiner, 1998](#bib27){ref-type="other"}).

Toxicity and response evaluation
--------------------------------

Toxicity, graded according to NCI common toxicity criteria (NCI-CTC version 2.0), was assessed by clinical and biological examinations at least weekly during a cycle, before each cycle and at the end of treatment. Dose-limiting toxicity was defined as the occurrence of one of the following events: neutropenia grade 4 with documented infection, persistent (more than 7 days) grade 4 neutropenia or grade 3 or 4 thrombocytopenia, thrombocytopenia necessitating platelet transfusions for a period of more than 7 days, or any nonhaematologic grade ⩾3 toxicity (except vomiting in the absence of adequate treatment, fever without infection, mucocitis, or transient, that is, resolved to grade 1 or 0 at the next treatment cycle in the case of hepatic toxicity). Antitumour efficacy was assessed every two cycles and/or at the end of treatment, according to the Response Evaluation Criteria in Solid Tumour (RECIST) criteria of the National Cancer Institute ([Therasse *et al*, 2000](#bib39){ref-type="other"}). Responses were centrally reviewed by two radiologists (DC and AG).

*O*^6^-alkylguanine-DNA alkyltransferase activity in PBMCs
----------------------------------------------------------

Blood samples were collected before cisplatin administration (day 0), on day 1 before the first and on day 5 few hours after the last temozolomide dose. Peripheral blood mononuclear cells were isolated by Ficoll separation and resuspended in EDTA/Tris buffer. *O*^6^-alkylguanine-DNA alkyltransferase activity in cell-free sonicates was determined by measuring the amount of radioactivity transferred from \[3H\]methylated substrate DNA to MGMT under protein-limiting conditions as previously described ([Watson and Margison, 2000](#bib42){ref-type="other"}). Specific activity was calculated as fmol *μ*g^−1^ DNA in the PBMC extract. DNA content was determined using the Picogreen dsDNA quantification kit (Molecular Probes, Invitrogen, Paisley, UK) according to the manufacturer\'s instructions. For each set of samples, a pellet of human lymphoblastoid cells (Raji) was included as an assay control and the inter- and intra-assay precision for these samples was 4.6 and 3.5%, respectively, over the whole study. In a separate study, replicate PBMC samples from the same volunteer gave an intrasubject variation of 2.1%. The limits of quantification were defined as 2.5 fmol for MGMT and 0.1 *μ*g ml^−1^ for DNA content. Several of the MGMT values in the post-temozolomide samples were below the lower limit of quantification. In these cases where the sample size was very small, but DNA was still quantifiable, it was reasonable to calculate an MGMT specific activity that would be the maximum possible value, rather than presenting a zero value. While the result would give an underestimate of MGMT inactivation, it was considered more appropriate in the context of our hypothesis to present this rather than an overestimate of inactivation. Statistical differences between treatment and toxicity groups were assessed by the nonparametric Mann--Whitney test.

RESULTS
=======

Patients\' characteristics
--------------------------

Between May 2001 and June 2002, 39 patients (25 males, 14 females) were included and treated in the study; patients\' characteristics are summarised in [Table 1](#tbl1){ref-type="table"}. The median age was 12 years 8 months, patients had a median Lansky or ECOG performance scores of 80% and 2, respectively. Predominant tumour types were brain tumours, malignant mesenchymal tumours and neuroblastoma. A total of 38 patients had received prior chemotherapy and/or radiation therapy, one had surgical tumour resection only. Five patients previously received cerebrospinal irradiation and 11 high-dose chemotherapy with autologous stem cell rescue. Six patients had bone marrow metastases at study entry. A total of 38 patients experienced between one and five tumour relapses, one tumour was refractory to prior treatment. Patient No. 007 enrolled in cohort B was deemed nonassessable for toxicity, as he died due to tumour progression within 18 days after treatment start.

Study treatment and compliance
------------------------------

In total, 39 patients received a total of 114 treatment cycles. In cohort A, 73 cycles were administered in 25 patients at three dose levels, and in cohort B, 42 cycles in 14 patients at two dose levels, in both cohorts, between one to seven cycles per patient (median 2). Cycles were started at days 26--65 (median 29). In cohort A, 16% of cycles (12 out of 73) were delayed by more than 7 days, 12% (nine out of 73) were administered with a 17--40% reduced temozolomide and/or cisplatin dose, in all but one due to haematological toxicity. In cohort B, 17% of cycles (seven out of 41) were delayed, 7% (three out of 41) introduced with a 33% reduced temozolomide dose. The median delay did not increase with treatment duration.

Dose-limiting toxicity and MTD
------------------------------

In total, 25 patients were evaluable for toxicity in cohort A, and 13 in cohort B. In all but one, DLT during the first cycle was haematological ([Table 2](#tbl2){ref-type="table"}). Overall, eight children experienced persistent grade 3 thrombocytopenia, six of them needed platelet transfusion support for a period of more than 7 days. Persistent grade 4 neutropenia was noted in three patients. One child had documented febrile infection during a persistent grade 4 neutropenia; one patient experienced grade 3 septicemia without neutropenia. According to the CRM, the recommended doses for less-heavily pretreated children were defined as cisplatin 80 mg m^−2^ and temozolomide 200 mg m^−2^ day^−1^ × 5, and cisplatin 80 mg m^−2^ and temozolomide 150 mg m^−2^day^−1^ × 5 for heavily pretreated children.

Dose escalation using the CRM
-----------------------------

[Figure 1](#fig1){ref-type="fig"} shows dose level and DLT in all treated patients. Patients of both cohorts were initially treated as a single group for dose escalation. The definition of cohort B was refined after patient 13. This modified the group assignment of previously included patients. The third DLT was no longer assigned to cohort A but to cohort B. Running estimates of MTD for both cohorts were updated; dose level 1 was recommended for patient 15 from cohort A and level 2 for patient 16 from cohort B. Patient 28 was first considered as a non-DLT, and dose level 3 was recommended. Had patient 28 been correctly evaluated at that time, then the trial would have come to a halt after patient 30. Ultimately, 25 and 14 patients were included in cohort A and B, respectively.

Haematologic toxicity
---------------------

Haematological toxicity was common. Grade 3 or 4 neutropenia was experienced by 72% (18 out of 25) of patients and in 45% (33 out of 73) cycles in cohort A and by 61% (eight out of 13) of patients and in 35% (14 out of 40) cycles in cohort B. Grade 4 neutropenia was persistent for more than 7 days in nine of the 15 cycles and five of 11 patients experiencing grade 4 toxicity. Grade 3 thrombocytopenia occurred in 44% (11 out of 25) of patients and in 25% (18 out of 73) cycles in cohort A and in 54% (seven out of 13) of patients and in 23% (nine out of 40) cycles in cohort B. Persistent grade 3 thrombocytopenia was noted in 12 of the 27 cycles and 10 of 18 patients. The frequency of grade 3 thrombocytopenia was correlated with treatment dose levels. The median nadir neutrophil and thrombocyte counts appeared during the fourth week of the treatment cycle. Neither neutropenia nor thrombocytopenia appeared cumulative.

Nonhaematologic toxicities
--------------------------

Nonhaematologic toxicities were mostly mild or moderate and appeared independent of dose level and study cohort. [Table 3](#tbl3){ref-type="table"} summarises grade 3 and 4 toxicities. The principle toxicities likely to be related to study treatment were acute nausea and vomiting. Despite premedication with ondansetron and corticoids, grade 1--2 nausea and/or vomiting occurred in 25% cycles and 39% of patients, grade 3--4 in 5 and 11%, respectively. Grade 1--3 asthenia was noted in 29% of patients. Three patients experienced four episodes of grade 3 or 4 septicaemias, one of them during a grade 4 neutropenia. Grade 3 renal toxicity was observed in one patient following intensive vomiting and subsequent dehydration. Toxicity recovered to grade 1 at the end of the cycle.

Grade 2--3 hearing loss, evaluated with audiograms, was noted in five (13%) patients at cumulative cisplatin doses of 100--460 mg m^−2^ (median 240 mg m^−2^). All these patients had prior irradiation to a brain stem glioma, medulloblastoma or ependymoma of the posterior fossa. None had signs of renal toxicity. In total, 12 patients included in the study had prior radiation therapy for a brain stem glioma or a tumour of the posterior fossa. One girl with a brain stem glioma treated with five cycles of cisplatin--temozolomide (400 mg m^−2^ cisplatin) had a normal audiogram at the end of the study; the other six patients had no audiogram evaluation after one or two treatment cycles.

Several patients experienced adverse events, including grade 1--4 pain, headache and neurological alterations, that occurred in general within the context of progressive disease (PD) and were considered secondary to their cancer rather than a consequence of cisplatin--temozolomide treatment.

Efficacy
--------

Five patients experienced partial tumour response (PR). A patient with an anaplastic ganglioglioma that had progressed previously following temozolomide and radiation therapy experienced a PR after six cycles at 80/150 mg m^−2^ and this continued after the seventh cycle with temozolomide alone. Progression occurred 9 months after treatment start. An anaplastic pleomorphic xanto-astrocytoma of the frontal lobe regressed after two cycles at 80/200 mg m^−2^. Surgical resection of the 2 × 2 mm^2^ tumour residue after seven cycles determined no viable tumour cells. However, shortly thereafter the patient relapsed and died due to tumour progression. A PR was observed in a brain stem glioma after one cycle at 100/200 mg m^−2^. Owing to ototoxicity, treatment continued with temozolomide alone until tumour progression occurred 6 months after the study treatment start. In cohort B, two boys with metastatic neuroblastomas previously treated with high-dose chemotherapy and stem cell rescue and a second line of chemotherapy, experienced nonconfirmed PR this being noted in one of the patients by computer tomographical analysis after four cycles. However, an mIBG scan had shown a slight reduction of fixation sites at cycle 2, but PD at cycle 4. The other patient experienced a PR by mIBG scintigraphy after two cycles; however, he progressed with multiple new lesions at cycle 4.

Four patients had stable disease for at least 6 months treated either with cisplatin--temozolomide or cisplatin--temozolomide followed by temozolomide alone: two patients with a brain stem glioma and one with a soft tissue clear cell sarcoma during 6 months, and one patient with a four times relapsing undifferentiated sarcoma during 11 months.

Follow-up
---------

Two patients with sarcomas and one with an ependymoma are alive at 30, 28 and 27 months after study entry, respectively. One patient was lost to follow-up after 7.6 months. After the end of the study, six patients had continued treatment with temozolomide alone for 2 to 5 months (median 3.5 months). These patients had experienced PR (two) or stable disease or objective clinical response (four) and were taken off study treatment due to auditory toxicity (three cases) or maximal cumulative cisplatin dose (three cases).

*O*^6^-alkylguanine-DNA alkyltransferase activity in PBMCs
----------------------------------------------------------

*O*^6^-alkylguanine-DNA alkyltransferase activity was evaluable in 33 patients at least at one time point ([Table 4](#tbl4){ref-type="table"}). Baseline MGMT activity (31 patients) varied from 2.8 to 52.5 Fm *μ*g^−1^ DNA with a median of 12.8 Fm *μ*g^−1^ DNA. *O*^6^-alkylguanine-DNA alkyltransferase in 27 patients after cisplatin administration ranged from 3.0 to 44.7 Fm *μ*g^−1^ DNA with a median of 12.4 Fm *μ*g^−1^ DNA; MGMT in 25 patients on day 5 ranged from \<0.4 to 31.3 Fm *μ*g^−1^ DNA with a median of 4.4 Fm *μ*g^−1^ DNA. There was a wide range of change in MGMT levels following treatment in individual patients. After cisplatin, while the mean and median MGMT activities were 116 and 102% of baseline levels, respectively, indicating no overall marked change, individual activities varied from 29 to 309% of baseline levels. Interestingly, in the two patients exhibiting the highest pretreatment levels (42.2 and 52.5 Fm *μ*g^−1^ DNA) there was significant reduction after cisplatin treatment to 12.4 and 27.2 Fm *μ*g^−1^ DNA, respectively. Significant (∼50%) reductions were also seen in four other patients with much lower pretreatment levels. Substantial (\>50%) increases in MGMT activity were seen in five patients. After treatment with temozolomide for 5 days, the mean and median MGMT activities were at most 65 and 34% of baseline levels, respectively, indicating an overall substantial inactivation of MGMT (*P*=0.0004; Mann--Whitney test). However, again, individual levels varied considerably, ranging from \<5 to 310% of pretreatment levels. Thus, in a total of 25 patients with evaluable samples at baseline and at day 5, 17 patients (68%) had MGMT depletion of more than 50%, two patients (8%) had MGMT depletion of less than 50%, three patients (12%) had an increase of MGMT of more than 50% and three patients (12%) had an increase of less than 50%. The greatest increases were seen in those patients with the lowest pretreatment levels, but the reasons for this are not evident. Depletion was seen at all dose levels tested and was independent of the treatment group, response or any other parameters.

In order to assess if there was any correlation between MGMT levels at baseline or after cisplatin--temozolomide treatment and haematological toxicity, we excluded data from Patient No. 007, who was not evaluable for toxicity. Patients experiencing thrombocytopenia grade 0--2 had higher levels of MGMT at baseline (median 14.5 Fm *μ*g^−1^, range 3.1--52.5 Fm *μ*g^−1^) and after CISTEM treatment (median 5.5 Fm *μ*g^−1^, range 0.6--31.3 Fm *μ*g^−1^) than patients with grade 3 toxicity (median 6.7 Fm *μ*g^−1^, range 2.8--15.9 Fm *μ*g^−1^ at baseline; *P*=0.0158; and median 2.2 Fm *μ*g^−1^, range 0.4--7.8 Fm *μ*g^−1^ at day 5; *P*=0.0123; [Figure 2](#fig2){ref-type="fig"}). There was no correlation between MGMT and neutropenia: grade 0--2 patients had a median value of 12.8 Fm *μ*g^−1^ (range 3.1--42.2 Fm *μ*g^−1^) and grade 3--4 patients a median of 12.3 Fm *μ*g^−1^ (range 2.8--52.5 Fm *μ*g^−1^) at baseline and a median of 4.6 Fm *μ*g^−1^ (range 0.4--31.3 Fm *μ*g^−1^) and 6.1 Fm *μ*g^−1^ (1.3--12.3 Fm *μ*g^−1^), respectively, on day 5.

In summary, temozolomide treatment for 5 days depleted MGMT in peripheral mononuclear cells in at least 76% of patients and low MGMT activity was correlated with severe thrombocytopenia during the first treatment cycle.

DISCUSSION
==========

The rationale for combining cisplatin and temozolomide was based on the potential for improved antitumour activity. Both have marked activity in paediatric malignancies; cisplatin is part of many protocols for solid tumours and temozolomide has shown activity in malignant gliomas ([Newlands *et al*, 1992](#bib22){ref-type="other"}; [Estlin *et al*, 1998](#bib9){ref-type="other"}). Both agents target DNA, although they kill cells by different mechanisms: temozolomide via methylation at the *O*^6^ position of guanine and the subsequent action of the mismatch repair system, whereas cisplatin produces DNA crosslinks preferentially via reaction at the N7 positions of guanine and adenine ([O\'Dwyer *et al*, 1997](#bib24){ref-type="other"}). Despite this, there is increasing evidence that inactivators of MGMT can enhance the toxicity of cisplatin ([Fishel *et al*, 2003](#bib10){ref-type="other"}). In addition, preclinical studies suggested that cisplatin can attenuate the expression of MGMT ([D\'Atri *et al*, 2000](#bib5){ref-type="other"}) resulting in increased sensitivity to temozolomide and additive tumour growth inhibition ([Piccioni *et al*, 1995](#bib32){ref-type="other"}). Although a clinical combination of temozolomide with cisplatin might be beneficial in terms of tumour responses, it is also possible that normal tissue toxicities may be increased, and this needed to be examined in phase I studies in the paediatric setting.

Based on the preclinical findings, in the present paediatric trial, cisplatin was administered as a 3-h infusion prior to temozolomide for 5 days. As the toxicity profiles of cisplatin and temozolomide are very distinct, we started the dose escalation of each agent at 80% of their single agent dose. This selection was appropriate as the results showed that the combination of the two drugs did not potentiate existing toxicities of the individual agents. The DLT of cisplatin--temozolomide after the first treatment cycle in children and adolescents was haematologic. This was consistent with the phase I data of the cisplatin--temozolomide combination in adult malignancies ([Britten *et al*, 1999](#bib4){ref-type="other"}), but also similar to paediatric data for temozolomide given as a single agent ([Estlin *et al*, 1998](#bib9){ref-type="other"}; [Nicholson *et al*, 1998](#bib23){ref-type="other"}; [Lashford *et al*, 2002](#bib16){ref-type="other"}). Subsequently, the MTD of the cisplatin--temozolomide combination for both cohorts (A and B) were similar to those of the previous studies. [Britten *et al* (1999](#bib4){ref-type="other"}) determined the recommended dose for the adult phase II study as temozolomide 200 mg m^−2^day^−1^ × 5 days and cisplatin 75 mg m^−2^ every 28 days. In contrast to our study, cisplatin was scheduled at day 1 beginning 4 h after the first of five daily doses of temozolomide. The paediatric phase I studies of the Children\'s Cancer Group and the UK group using temozolomide as single agent had stratified according to prior CSI and determined the MTD of temozolomide at 215 mg m^−2^/day × 5 administered every 21 days or 200 mg m^−12^/day × 5 every 28 days for children and adolescents in the non-CSI group and 180 mg m^−2^ day^−1^ × 5 in the CSI-treated group ([Estlin *et al*, 1998](#bib9){ref-type="other"}; [Nicholson *et al*, 1998](#bib23){ref-type="other"}). Both of these paediatric dose-finding studies did not include patients after high-dose chemotherapy or with bone marrow involvement at study entry in the heavily pretreated cohort. These patients often have reduced thrombocytopoiesis, which may have contributed to the lower dose of temozolomide tolerated by our patients in cohort B.

Non-haematological toxicity in children was mostly mild or moderate and did not differ from those known for both single agents. Owing to the potential renal and auditory toxicity of cisplatin, the study limited the maximal cumulative dose to 600 mg m^−2^, including prior treatment. Nevertheless, we observed five patients with hearing loss of more than 50 db at 4000 or 2000 Hz at lower doses. It is worth noting that all five patients had prior irradiation to the brain including a significant radiation dose to the ear region. Our findings confirmed a reduced maximal tolerated cumulative dose of cisplatin in these children. We did not consider that the association of temozolomide had any contribution to this toxicity. In the study of Britten *et al*, three out of 15 patients experienced grade 3 hearing loss and three further patients grade 2 tinnitus without subjective hearing loss ([Britten *et al*, 1999](#bib4){ref-type="other"}). There was no additional information given on the prior treatment of these patients.

Both temozolomide and cisplatin have potential emetic effects. Nausea-vomiting were observed in half of the patients despite premedication; however, they were mostly mild to moderate and manageable with standard antiemetic treatment. The lack of additive emetic effects of the cisplatin--temozolomide combination had been also reported in adult patients ([Britten *et al*, 1999](#bib4){ref-type="other"}). In addition, Britten *et al* had performed pharmacokinetic studies that showed no pharmacokinetic interactions between the two drugs. Thus, cisplatin and temozolomide can be combined at their MTD without additive toxicity profiles; however cumulative toxicity of cisplatin limits the duration of this combination treatment.

A distinguishing feature of this dose finding study was the use of the CRM. The CRM firstly enabled us to perform a single trial with dose-escalations in two stratified groups. The design allows for a more efficient use of the data so that both groups can be evaluated simultaneously, sharing information and thereby improving overall identification of both MTDs. Secondly, the CRM is expected to provide a more accurate estimate of both MTDs since they are identified on the basis of all collected observations. The CRM determined level 2 for the nonheavily pretreated children and level 1 for the heavily pretreated children as recommended doses for the combination. The classical dose escalation would have determined level 1 and minus 1, respectively, which are below the single MTD doses of temozolomide for these cohorts. Thus, the classical design would have been too conservative in its estimate of MTDs. Discussion is ongoing about the accuracy of the dose-finding methodologies used in phase 1 trials ([Korn *et al*, 1999](#bib15){ref-type="other"}; [O\'Quigley, 1999](#bib25){ref-type="other"}). The currently ongoing phase II trial in malignant glioma, which is using the doses defined by the CRM, will give further clarification for this combination treatment.

Encouraging tumour responses were observed in children with recurrent gliomas and brain stem gliomas. The response of an anaplastic ganglioglioma in a girl who was one of three siblings of a family with a Li--Fraumeni syndrome with an identified p53 mutation (R273H) was interesting as she had progressed previously with temozolomide and irradiation treatment. P53 mutations and lack of p21-mediated cell arrest have been suggested to render cancer cells resistant to temozolomide ([Tentori *et al*, 1998](#bib38){ref-type="other"}; [Hirose *et al*, 2001](#bib13){ref-type="other"}; [Bocangel *et al*, 2002](#bib2){ref-type="other"}), although the data on the implication of p53 in temozolomide resistance are not consistent ([Middlemas *et al*, 2000](#bib19){ref-type="other"}). Recently, the results of phase II studies combining cisplatin and temozolomide in adult patients with malignant gliomas were published. For 20 patients with recurrent glioblastomas and 13 with anaplastic astrocyctomas, [Silvani *et al* (2003](#bib35){ref-type="other"}) reported progression-free survival at 12 months of 14 and 17%, respectively. [Brandes *et al* (2004](#bib3){ref-type="other"}) reported responses in relapsing chemotherapy-naive glioblastomas in 10 of 49 assessed patients and 34% progression-free survival at 6 months. These findings and those of the present study have resulted in a phase II study in children and adolescents with newly diagnosed and relapsing high-grade gliomas (SFCE and UKCCSG).

A number of clinical trials involving temozolomide and related alkylating agents have included assessments of the levels of expression and depletion of the DNA repair protein MGMT and the majority of studies have examined effects in PBMCs as a surrogate tissue. In the present study, baseline PBMC MGMT activity exhibited a very wide range with values between 2.8 and 52.5 (mean 14.1±1.0) Fm *μ*g^−1^ DNA. This was somewhat higher than previous values ([Middleton *et al*, 2000b](#bib21){ref-type="other"}: range 2.2--25.6, mean 12.6) but similar to other ongoing studies (range 2.3--51.6, mean 15.5: GPM unpublished results). Another study of adult patients has reported a range of ∼0.6 to ∼19 Fm *μ*g^−1^ DNA and a much lower mean of 6.9±4.7 Fm *μ*g^−1^ DNA ([Tolcher *et al*, 2003](#bib40){ref-type="other"}). Some of these differences may be a consequence of the age or disease status of the study groups.

Cisplatin had no overall effect on PBMC MGMT levels, and although we did observe a significant reduction in those patients with high baseline MGMT activity, reductions were also seen in some patients with intermediate activity, while there were increases in others. To our knowledge, no evaluation of MGMT depletion in PBMCs in patients following cisplatin exists to date so that these observations remain to be confirmed. At present, our results using the current doses and schedule do not support the possibility that MGMT depletion might be consistently achieved by cisplatin in a way that could be exploited clinically, although further studies are warranted.

*O*^6^-alkylguanine-DNA alkyltransferase levels in PBMCs were reduced in most patients at the end of temozolomide treatment at all dose levels although it must be noted that part of this depletion might be due to a delayed effect of cisplatin. Previous studies reporting MGMT in adult PBMCs have also shown a range of extents of depletion by temozolomide. A variety of dose regimen and schedules have been examined but complete depletion of MGMT has been observed in very few patients and very wide variations in depletion are always observed ([Lee *et al*, 1994](#bib17){ref-type="other"}; [Gander *et al*, 1999](#bib11){ref-type="other"}; [Middleton *et al*, 2000b](#bib21){ref-type="other"}; [Tolcher *et al*, 2003](#bib40){ref-type="other"}). The reasons for this have yet to be established.

We did not attempt to correlate the initial levels or depletion of MGMT in PBMCs with tumour response, since this was a phase I combination trial including patients with different malignancies and multiple prior lines of treatment. However, regarding toxicity, we found that the grade of thrombocytopenia during cycle 1 was correlated with low baseline levels of MGMT though this was not evident for neutropenia. Although our evaluations are in a limited number of samples and need to be confirmed and extended by further studies, they are supported by previous studies. Thus, lower MGMT activities in PBMCs have been associated with increased haematological toxicity in a phase II study of temozolomide in adult melanoma patients ([Middleton *et al*, 2000b](#bib21){ref-type="other"}) and inactivation of MGMT was correlated with haematological toxicity in a phase I study of temozolomide ([Tolcher *et al*, 2003](#bib40){ref-type="other"}). Nevertheless, to address the questions of MGMT inactivation by cisplatin in relation to tumour responses and toxicities, it would be necessary to undertake larger studies, ideally in direct comparison with equivalent numbers of patients receiving temozolomide alone.

CONCLUSION
==========

The combination of cisplatin and temozolomide is well tolerated in children and adolescents, generating no toxicity greater than that of the single agents. The antitumour activity observed in the current study led to the ongoing evaluation in a phase II clinical setting in children with newly diagnosed and recurrent malignant gliomas.

We thank Xavier Paoletti (Hopital Bichat-Claude Bernard, Paris) for fruitful discussions on the study design.

![Dose escalation according to the CRM. Patients in cohort A (open diamond) and cohort B (closed square) were treated at the dose levels indicated. Arrows indicate observed DLTs, ^\*^ indicates that the patient was not evaluable for toxicity and was excluded from the CRM.](93-6602740f1){#fig1}

![MGMT specific activity (SA: Fm *μ*g^−1^ DNA) in PBMC cells at baseline and depletion at day 5 of cisplatin--temozolomide treatment in samples of patients evaluable for toxicity in relation to grade of thrombocytopenia experienced during the first treatment cycle. The median values for each group are shown as a thick horizontal bar.](93-6602740f2){#fig2}

###### 

Characteristics of participants *n*=39

  **Stratum**                               **A without HDCT^a^**/**CSI^b^**/**BM^c^ (*N*=25)**       **B HDCT/CSI/BM (*N*=14)**             **Overall (*N*=39) (%)**
  ---------------------------------------- ----------------------------------------------------- ------------------------------------ --------------------------------------
  *Age at study entry*                                                                                                                
   Median                                                    12 years 8 months                             12 year 1 month                       12 year 8 months
   Range                                           1 year 10 months--19 years 11 months           4 years 5 months--18 year 9 months   1 year 10 months--19 years 11 months
                                                                                                                                                         
  *Gender*                                                                                                                            
   Male                                                             12                                            13                                 25 (64%)
   Female                                                           13                                            1                                  14 (36%)
                                                                                                                                                         
  Lansky performance status                                       *N*=12                                        *N*=7                                 *N*=19
  Median (range)                                              80% (40--100%)                                90% (80--100%)                        80% (40--100%)
                                                                                                                                                         
  ECOG performance status                                         *N*=13                                        *N*=7                                 *N*=20
  Median (range)                                                 0 (0--3)                                      2 (1--3)                              2 (0--3)
                                                                                                                                                         
  *Diagnoses*                                                                                                                                            
   Central nervous system (CNS) tumous                                                                                                                *N*=18
    Malignant glioma                                                 2                                            0                                     2
    Anaplastic ganglioglioma                                         1                                            0                                     1
    Anapl. pleomorphic xanto-astrocytoma                             1                                            0                                     1
    Brain stem glioma                                                7                                            0                                     7
    Oligodendroglioma                                                1                                            0                                     1
    Ependymoma                                                       3                                            0                                     3
    PNET                                                             1                                            0                                     1
    Medulloblastoma                                                  0                                            2                                     2
                                                                                                                                                         
   Non-CNS tumours                                                                                                                                    *N*=21
    Neuroblastoma                                                    0                                            4                                     4
    Rhabdomyosarcoma                                                 1                                            1                                     2
    Ewing tumours                                                    1                                            2                                     3
    Neurofibrosarcoma                                                1                                            1                                     2
    Other sarcoma (indiff, fusiforme)                                3                                            3                                     6
    Desmoplastic small round cell tumour                             1                                            0                                     1
    Nephroblastoma                                                   0                                            1                                     1
    Retinoblastoma                                                   1                                            0                                     1
    Melanoma (CNS metastases)                                        1                                            0                                     1
                                                                                                                                                         
  Tumour refractory at study entry                                   1                                            0                                     1
  *Tumour relapsing*                                                24                                            14                                    38
   Median (range)                                                1 (1--3)                                      2 (1--5)                              2 (1--5)
                                                                                                                                                         
  *Prior therapy*                                                                                                                     
   Surgery only                                                      1                                            0                                     1
   Chemotherapy+ radiation therapy                                  16                                            9                                     25
   Chemotherapy only                                                 5                                            5                                     10
   Radiation therapy only                                            3                                            0                                     3
   Craniospinal irradiation                                          0                                            5                                     5
   High-dose chemotherapy                                            0                                            11                                    11
   Bone marrow involvement                                           0                                            6                                     6
   Prior cisplatin                                                 *N*=4                                        *N*=4                                 *N*=8
   Median mg m^−2^ (range)                                    245 (120--372)                                300 (140--400)                        245 (120--400)
   Prior nephrectomy                                                 0                                            2                                     2
                                                                                                                                                         
  Patients evaluable for toxicity                                   25                                            13                                    38

High-dose chemotherapy and peripheral stem cell rescue

Craniospinal irradiation

Bone marrow involvement.

###### 

Dose-limiting toxicity at cycle one 38 patients

  **Dose level**   **Cohort A**   **Cohort B**                                                              
  ---------------- -------------- ------------------------------------------------------------------ ------ --------------------------------------------------
  80/150           1/6            Platelet transfusion \>7 days                                      2/11   Thrombocytopenia G3 \>7 days
                                                                                                            Platelet transfusion \>7 days
                                                                                                             
  80/200           3/11           Febrile neutropenia G4 and platelet transfusion \>7 days           1/2    Neutropenia G4 and platelet transfusion \>7 days
                                  Platelet transfusion \>7 days                                              
                                  Septicaemia G3                                                             
                                                                                                             
  100/200          3/8            Infection during neutropenia G4 and thrombocytopenia G3 \>7 days   0       
                                  Platelet transfusion \>7 days                                              
                                  Neutropenia G4 \>7 days                                                    

###### 

Grade 3 and 4 nonhaematological toxicities

                                       **NCI grade**  **Cycles (*N*=113)**   **Imputability^a^**   **Total (%)**   **Patients (*N*=38)**   **%**
  ----------------------------------- --------------- ---------------------- --------------------- --------------- ----------------------- -------
  General: asthenia/fatigue                 G3        4                      2                     3.5             4                       10.5
                                                                                                                                            
  Gastrointestinal: nausea-vomiting         G3        3                      3                     2.7             1                       2.6
                                            G4        3                      1                     2.7             3                       7.9
                                                                                                                                            
  *Infection*                                                                                                                              
   Infection during neutropenia             G3        1                      0                     0.9             1                       2.6
   Septicaemia                              G3        2                      1                     1.8             1                       2.6
                                            G4        1                      1                     0.9             1                       2.6
   Urinary tract infections                 G3        1                      0                     0.9             1                       2.6
                                                                                                                                            
  *Pain*                                                                                                                                   
   Headache                                 G4        1                      0                     0.9             1                       2.6
   Unspecified                             G3--4      2                      0                     1.8             2                       5.3
                                                                                                                                            
  *Neurological*                                                                                                                           
   Neurological alteration                 G3--4      3                      0                     2.7             3                       7.9
   Reduced vigilance, hallucination         G3        1                      0                     0.9             1                       2.6
   Intracranial hypertension                G3        1                      0                     0.9             1                       2.6
                                                                                                                                            
  *Infection*                                                                                                                               
   Infection in neutrocytopenia             G3        1                      1                     0.9             1                       2.6
   Septicaemia                              G3        2                      1                     1.8             1                       2.6
                                            G4        1                      1                     0.9             1                       2.6
   Urinary tract infections                 G3        1                      0                     0.9             1                       2.6
                                                                                                                                            
  *Renal insufficiency*                                                                                                                    
   Creatinaemia                             G3        1                      1                     0.9             1                       2.6
                                                                                                                                            
  *Ototoxicity (audiogram)*                                                                                                                
   Hypacusis                                G3        2                      2                     1.8             2                       5.3

Events considered certain, probably or possibly related to study medication.

###### 

MGMT activity in peripheral blood mononuclear cells

           **ATase SA (Fm *μ*g^−1^)**   **% Activity remaining following**                            
  -------- ---------------------------- ------------------------------------ ------------- ---------- ---------
  25\#     2.8                                                               **7.8**                  **276**
  2        3.1                          3.7                                  5.5           119        177
  24\#     3.9                          11.9                                 **4.1**       309        **107**
  7        3.9                          5.4                                  0.85          140        22
  20       3.9                                                               12.1                     310
  13\#     4.3                          5.1                                  **0.4**       120        **9**
  36       4.9                          3.6                                                74          
  39       5.9                          6.8                                  1.1           115        19
  9        7.1                          9.0                                                127         
  10\#     7.5                          3.1                                  **3.1**       41         **41**
  38\#     7.8                          3                                    **1.3**       38         **17**
  6\#      8.2                          9.0                                  **0.7**       110        **9**
  15       8.3                          14.3                                 9.0           173        109
  4        10.7                         10.9                                 2.6           102        25
  17\#     11.0                         5.4                                  **4.3**       49         **39**
  12       12.8                         5.5                                  6.2           43         48
  21       12.9                                                                                        
  31\#     13.1                                                              **0.6**                  **5**
  30\#     13.5                         35                                   **2.9**       259        **22**
  22       15.5                         33.3                                 12            215        77
  28       15.9                         22.4                                               141         
  14       15.9                         14.7                                 5.5           92         35
  3        17.5                         15.4                                 10.1          88         57
  18       19.2                         44.7                                 4.6           233        24
  16\#     19.3                         13.4                                 **3.3**       69         **17**
  23       21.2                         18.4                                               87          
  29       25.3                         33.3                                               132         
  11\#     27.7                         25.2                                 **4.4**       91         **16**
  33       28.4                         24                                   31.3          85         110
  19       42.2                         12.4                                 14.5          29         34
  34       52.5                         27.2                                 12.3          52         24
                                                                                                       
  Mean     14.4                         15.4                                 6.4           116        65
  Median   12.8                         12.4                                 4.4           102        34
  Range    2.8--52.5                    3.0--33.3                            \<0.4--31.3   29--309%   5--310%

Values in bold are maximum values for sample in \# marked patient.
